DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
that's - 1 They're - 1 AJ Loiacono - 1 Li Ran - 1 James Gelfand - 1 Eli Lilly's - 1 Ozempic - 1 drugmakers - 1
Top related locs:
Novo Xinhua
Top related orgs:
Morning - 1 Novo Nordisk - 1 Getty - 1 Workers - 1 Drugmakers - 1 Therapeutics - 1 Blue - 1 Mayo Clinic - 1

Search resuls for: "Navitus"


2 mentions found


☆ Inside your company's struggle over whether to pay for hot, new weight-loss drugs
  + stars: | 2023-06-20 | by ( ) www.businessinsider.com   time to read: +10 min
Americans are clamoring for new weight-loss drugs, but companies aren't rushing to pay for them. At most, half of US employers help pay for weight-loss drugs for their workers, according to several estimates. "The drug companies, providers, and patient groups are insisting that weight loss will improve health and therefore offset these massive costs. Known as GLP-1 agonists, the drugs — Wegovy and Ozempic from Novo Nordisk and Eli Lilly's Mounjaro — mimic a gut hormone known as glucagon-like peptide 1, helping to suppress people's appetites and slow their digestion. Brent Eberle, the chief pharmacy officer at Navitus, said very few of the employers that worked with his pharmacy-benefit manager paid for weight-loss drugs.
Persons: that's, They're, AJ Loiacono, Li Ran, James Gelfand, Eli Lilly's, Ozempic, drugmakers, Brent Eberle, Navitus, Eberle, it's, Pat Gleason, Gleason, Wegovy, Eli Lilly, Lilly, Florian Gaertner, Loiacono Organizations: Morning, Novo Nordisk, Getty, Workers, Drugmakers, Therapeutics, Blue, Mayo Clinic, and Drug Administration, Capital Locations: Novo, Xinhua
☆ How big companies are contending with a frenzy of demand for Ozempic from their workers
  + stars: | 2023-05-10 | by ( ) www.businessinsider.com   time to read: +5 min
Demand for expensive weight-loss drugs such as Ozempic and Wegovy is soaring. Companies that foot the bill for their workers' health coverage are mulling whether to pay for them. Across the US, companies are facing a critical decision: whether to foot the bill for the expensive weight-loss drugs that have exploded in popularity in recent months. Andrews estimated that more than half the companies in the alliance covered weight-loss drugs. Andrews' comments offer a window into how big US companies are grappling with the rising demand for and high costs of weight-loss treatment.
0 next >>
Total: 2